Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: LCL161
Drug: paclitaxel

First Posted Date: 2012-06-12

Last Posted Date: 2016-10-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 209

Registration Number: NCT01617668

Locations: 🇺🇸
Stanford University Medical Center Stanford, Stanford, California, United States
🇺🇸
Vanderbilt University Medical Center Vanderbilt - Thompson Ln, Nashville, Tennessee, United States
🇺🇸
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States

and more 11 locations

Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

Phase 3

Completed

Conditions: Pediatric Hypertension With or Without CKD

Interventions: Drug: VAL489
Drug: VAL489 matching placebo

First Posted Date: 2012-06-12

Last Posted Date: 2017-09-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT01617681

Locations: 🇵🇱
Novartis Investigative Site, Warszawa, Poland

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ENA713
Drug: Active Comparator

First Posted Date: 2012-06-08

Last Posted Date: 2016-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 216

Registration Number: NCT01614886

Locations: 🇯🇵
Novartis Investigative Site, Shimonoseki-city, Yamaguchi, Japan

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Placebo
Drug: Olmesartan
Drug: LCZ696

First Posted Date: 2012-06-08

Last Posted Date: 2015-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 588

Registration Number: NCT01615198

Locations: 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: NVA237
Drug: Tiotropium
Drug: Placebo to tiotropium
Drug: Placebo to NVA237
Drug: salbutamol/albuterol

First Posted Date: 2012-06-07

Last Posted Date: 2014-04-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 657

Registration Number: NCT01613326

Locations: 🇨🇳
Novartis Investigative Site, Taipei County, Taiwan

Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer

Phase 2

Withdrawn

Conditions: Treatment for Metastatic or Locally Advanced Cervical Cancer

Interventions: Drug: BKM120

First Posted Date: 2012-06-07

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01613677

Locations: 🇧🇷
Novartis Investigative Site, Rio de Janiero, RJ, Brazil

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Chronic Myelomonocytic Leukemia (CMML)

Interventions: Drug: Panobinostat

First Posted Date: 2012-06-07

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01613976

Locations: 🇯🇵
Novartis Investigative Site, Kyoto, Japan

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Interventions: Drug: AUY922
Drug: BYL719

First Posted Date: 2012-06-07

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01613950

Locations: 🇺🇸
Massachusetts General Hospital Mass General 2, Boston, Massachusetts, United States
🇺🇸
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston, Texas, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: NVA237

First Posted Date: 2012-06-07

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01613690

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Conditions: Gastrointestinal Stromal Tumor

First Posted Date: 2012-06-06

Last Posted Date: 2015-04-24

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01613053

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy